Tranexamic acid (TXA) is an antifibrinolytic agent commonly used for the treatment or
prevention of bleeding. Indications for TXA are diverse, including heavy menstrual bleeding …

Clinically significant bleeding can occur as a consequence of surgery, trauma, obstetric
complications, anticoagulation, and a wide variety of disorders of hemostasis. As the causes …

Tranexamic acid (TXA) is an anti-fibrinolytic agent that acts by inhibiting plasminogen
activation and fibrinolysis. Although its first clinical use dates back more than 50 years, this …

Background Antifibrinolytic agents such as tranexamic acid (TXA) are commonly used as
adjunctive therapies to prevent and treat excessive bleeding. In non-surgical settings, TXA is …

Objectives We review the evidence for tranexamic acid (TXA) for the treatment and
prevention of bleeding caused by surgery, trauma and bleeding disorders. We highlight …

Intravenous tranexamic acid (TXA) reduces death because of bleeding in patients with
trauma and postpartum haemorrhage. However, in some settings intravenous injection is not …

The publication of the Clinical Randomization of an Antifibrinolytic in Significant
Hemorrhage-2 (CRASH-2) study and its intense dissemination prompted a renaissance for …

Objective: The aim of this study is critically to review the available evidence regarding the
use, efficacy and safety of tranexamic acid in the management of hemorrhage during …

Experience with tranexamic acid, an indirect fibrinolytic inhibitor, started as soon as it was
released from Shosuke Okamoto's lab in the early 1960s. It was first prescribed to females …

Background A number of clinical systematic review and meta-analysis have been published
on the use of tranexamic in the obstetric setting. The aim of this meta-analysis was to …